open access

Ahead of print
Research paper
Published online: 2021-01-18
Get Citation

Lung cancer in women: is gynecological and obstetrical history important?

Anna Trojnar, Joanna Domagała-Kulawik
DOI: 10.5603/OCP.2021.2021.0004

open access

Ahead of print
ORIGINAL ARTICLES
Published online: 2021-01-18

Abstract

Introduction. Lung cancer remains the most frequent cause of death related to cancers, reaching 1.8 mln worldwide. We observe globally that the incidence of lung cancer in the never smokers affects women disproportionately more often than men. 

Material and methods. The aim of the study was to analyse the data about women suffering from lung cancer, with particular emphasis on their gynecological and obstetrical history. Women with confirmed primary lung cancer were evaluated (n = 29). Information about smoking, gynecological and obstetrical history was obtained from a self-administered questionnaire. Demographic data were also collected. 

Results. The most frequent lung cancer was adenocarcinoma (51.7%), followed by squamous-cell carcinoma (31.0%) and small-cell lung cancer (17.2%). Epidermal growth factor receptor (EGFR) mutations were present in 3 cases. The vast majority of women were smokers (89.7%) with median 30 pack years (IQR 20–48). Evaluating the TNM classification, the highest number of patients was classified to stage III (44.8%). The median age of menarche was 14 years, menopause — 50 years, the number of days with bleeding in the menstrual cycle — 4 and the length of the menstrual cycle — 28 days. An overwhelming majority of women have given birth to a child. Women reported extended menstrual cycles as the most frequent menstrual disorder (6 cases, 20.7%). Hormone replacement therapy and intrauterine contraceptive device use were declared in 10.3%. 

Conclusions. The results based on the small group of patients did not reveal any significant gynecological dysfunctions in our sample group with lung cancer.

Abstract

Introduction. Lung cancer remains the most frequent cause of death related to cancers, reaching 1.8 mln worldwide. We observe globally that the incidence of lung cancer in the never smokers affects women disproportionately more often than men. 

Material and methods. The aim of the study was to analyse the data about women suffering from lung cancer, with particular emphasis on their gynecological and obstetrical history. Women with confirmed primary lung cancer were evaluated (n = 29). Information about smoking, gynecological and obstetrical history was obtained from a self-administered questionnaire. Demographic data were also collected. 

Results. The most frequent lung cancer was adenocarcinoma (51.7%), followed by squamous-cell carcinoma (31.0%) and small-cell lung cancer (17.2%). Epidermal growth factor receptor (EGFR) mutations were present in 3 cases. The vast majority of women were smokers (89.7%) with median 30 pack years (IQR 20–48). Evaluating the TNM classification, the highest number of patients was classified to stage III (44.8%). The median age of menarche was 14 years, menopause — 50 years, the number of days with bleeding in the menstrual cycle — 4 and the length of the menstrual cycle — 28 days. An overwhelming majority of women have given birth to a child. Women reported extended menstrual cycles as the most frequent menstrual disorder (6 cases, 20.7%). Hormone replacement therapy and intrauterine contraceptive device use were declared in 10.3%. 

Conclusions. The results based on the small group of patients did not reveal any significant gynecological dysfunctions in our sample group with lung cancer.

Get Citation

Keywords

lung cancer; women; gynecological history; estrogen; smoking

About this article
Title

Lung cancer in women: is gynecological and obstetrical history important?

Journal

Oncology in Clinical Practice

Issue

Ahead of print

Article type

Research paper

Published online

2021-01-18

DOI

10.5603/OCP.2021.2021.0004

Keywords

lung cancer
women
gynecological history
estrogen
smoking

Authors

Anna Trojnar
Joanna Domagała-Kulawik

References (32)
  1. WHO, International Agency for Research on Cancer (Globocan 2018) . https://gco.iarc.fr/today/data/factsheets/cancers/15-Lung-fact-sheet.pdf.
  2. Krzakowski M, Jassem J, Antczak A. Cancer of the lung, pleura and mediastinum. Oncol Clin Pract. 2019; 15.
  3. Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68(6): 394–424.
  4. Giovino G, Mirza S, Samet J, et al. Tobacco use in 3 billion individuals from 16 countries: an analysis of nationally representative cross-sectional household surveys. The Lancet. 2012; 380(9842): 668–679.
  5. Wakelee HA, Chang ET, Gomez SL, et al. Lung cancer incidence in never smokers. J Clin Oncol. 2007; 25(5): 472–478.
  6. Koo LC, Ho JH. Worldwide epidemiological patterns of lung cancer in nonsmokers. Int J Epidemiol. 1990; 19 Suppl 1: S14–S23.
  7. Subramanian J, Govindan R. Lung cancer in never smokers: a review. J Clin Oncol. 2007; 25(5): 561–570.
  8. Rodriguez-Lara V, Hernandez-Martinez JM, Arrieta O. Influence of estrogen in non-small cell lung cancer and its clinical implications. J Thorac Dis. 2018; 10(1): 482–497.
  9. De Matteis S, Consonni D, Pesatori AC, et al. Are women who smoke at higher risk for lung cancer than men who smoke? Am J Epidemiol. 2013; 177(7): 601–612.
  10. Rosell R, Moran T, Queralt C, et al. Spanish Lung Cancer Group. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med. 2009; 361(10): 958–967.
  11. Domagala-Kulawik J, Trojnar A. Lung cancer in women in 21th century. J Thorac Dis. 2020; 12(8): 4398–4410.
  12. Tam A, Morrish D, Wadsworth S, et al. The role of female hormones on lung function in chronic lung diseases. BMC Womens Health. 2011; 11: 24.
  13. Rodriguez-Lara V, Peña-Mirabal E, Baez-Saldaña R, et al. Estrogen receptor beta and CXCR4/CXCL12 expression: differences by sex and hormonal status in lung adenocarcinoma. Arch Med Res. 2014; 45(2): 158–169.
  14. Siegfried JM, Stabile LP. Estrongenic steroid hormones in lung cancer. Semin Oncol. 2014; 41(1): 5–16.
  15. Berardi R, Morgese F, Santinelli A, et al. Hormonal receptors in lung adenocarcinoma: expression and difference in outcome by sex. Oncotarget. 2016; 7(50): 82648–82657.
  16. Weinberg OK, Marquez-Garban DC, Fishbein MC, et al. Aromatase inhibitors in human lung cancer therapy. Cancer Res. 2005; 65(24): 11287–11291.
  17. Niikawa H, Suzuki T, Miki Y, et al. Intratumoral estrogens and estrogen receptors in human non-small cell lung carcinoma. Clin Cancer Res. 2008; 14(14): 4417–4426.
  18. Abe K, Miki Y, Ono K, et al. Highly concordant coexpression of aromatase and estrogen receptor beta in non-small cell lung cancer. Hum Pathol. 2010; 41(2): 190–198.
  19. Słowikowski BK, Lianeri M, Jagodziński PP. Exploring estrogenic activity in lung cancer. Mol Biol Rep. 2017; 44(1): 35–50.
  20. Siegfried JM, Hershberger PA, Stabile LP, et al. Estrogen receptor signaling in lung cancer. Semin Oncol. 2009; 36: 524–531.
  21. Ben Khedher S, Neri M, Papadopoulos A, et al. Menstrual and reproductive factors and lung cancer risk: A pooled analysis from the international lung cancer consortium. Int J Cancer. 2017; 141(2): 309–323.
  22. Gahr S, Stoehr R, Geissinger E, et al. EGFR mutational status in a large series of Caucasian European NSCLC patients: data from daily practice. Br J Cancer. 2013; 109(7): 1821–1828.
  23. Canelón SP, Boland MR. A systematic literature review of factors affecting the timing of menarche: the potential for climate change to impact women's health. Int J Environ Res Public Health. 2020; 17(5).
  24. Zhang Y, Yin Z, Shen L. Menstrual factors, reproductive factors and lung cancer risk: a metaanalysis. Zhongguo Fei Ai Za Zhi. 2012; 15: 701–719.
  25. Schwartz AG, Ray RM, Cote ML, et al. Hormone Use, Reproductive History, and Risk of Lung Cancer: The Women's Health Initiative Studies. J Thorac Oncol. 2015; 10(7): 1004–1013.
  26. Pesatori AC, Carugno M, Consonni D, et al. Reproductive and hormonal factors and the risk of lung cancer: the EAGLE study. Int J Cancer. 2013; 132(11): 2630–2639.
  27. Broekmans FJ, Soules MR, Fauser BC. Ovarian aging: mechanisms and clinical consequences. Endocr Rev. 2009; 30(5): 465–493.
  28. Min L, Wang F, Liang S, et al. Menopausal status and the risk of lung cancer in women: A PRISMA-compliant meta-analysis. Medicine (Baltimore). 2017; 96(26): e7065.
  29. Slatore CG, Chien JW, Au DH, et al. Lung cancer and hormone replacement therapy: association in the vitamins and lifestyle study. J Clin Oncol. 2010; 28(9): 1540–1546.
  30. Bae JM, Kim EH. Hormonal replacement therapy and the risk of lung cancer in women: an adaptive meta-analysis of cohort studies. J Prev Med Public Health. 2015; 48(6): 280–286.
  31. Jin C, Lang B. Hormone replacement therapy and lung cancer risk in women: a meta-analysis of cohort studies: Hormone replacement therapy and lung cancer risk. Medicine (Baltimore). 2019; 98(51): e17532.
  32. Jeon KH, Shin DW, Han K, et al. Female reproductive factors and the risk of lung cancer in postmenopausal women: a nationwide cohort study. Br J Cancer. 2020; 122(9): 1417–1424.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl